abstract: BACKGROUND: Every year, 2  9 million newborn babies die worldwide. A meta-analysis of four cluster-randomised controlled trials estimated that home visits by trained community members in programme settings in Ghana and south Asia reduced neonatal mortality by 12% (95% CI 5-18). We aimed to estimate the costs and @entity4 in a programme setting. METHODS: We prospectively collected detailed cost data alongside the Newhints trial, which tested the effect of a home-visits intervention in seven districts in rural Ghana and showed a reduction of 8% (95% CI -12 to 25%) in neonatal mortality. The intervention consisted of a package of home visits to pregnant @entity0 and their babies in the first week of life by community-based surveillance volunteers. We calculated incremental cost-effectiveness ratios (ICERs) with Monte Carlo simulation and one-way sensitivity analyses and characterised uncertainty with cost-effectiveness planes and cost-effectiveness acceptability curves. We then modelled the potential cost-effectiveness for baseline neonatal mortality rates of 20-60 @entity1 per 1000 livebirths with use of a meta-analysis of effectiveness estimates. FINDINGS: In the 49 zones randomly allocated to receive the Newhints intervention, a mean of 407 (SD 18) community-based surveillance volunteers undertook home visits for 7848 pregnant @entity0 who gave birth to 7786 live babies in 2009. Annual economic cost of implementation was US 203   998, or  0  53 per @entity0 . In the base-case analysis, the Newhints intervention cost a mean of  10   343 (95% CI 2963 to -7674) per newborn life saved, or  352 (95% CI 104 to -268) per discounted life-year saved, and had a 72% chance of being highly cost effective with respect to Ghana's 2009 gross domestic product per @entity0 . Key determinants of cost-effectiveness were the discount rate, protective effectiveness, baseline neonatal mortality rate, and implementation costs. In the scenarios modelled with the meta-analysis results, the @entity3 increased from  127 per life-year saved at a neonatal mortality rate of 60 @entity1 per 1000 livebirths, to  379 per life-year saved at a rate of 20 @entity1 per 1000 livebirths. The strategy had at least a 99% probability of being highly cost effective for lower-middle-income countries in all neonatal mortality rate scenarios modelled, and at least a 95% probability of being highly cost effective for low-income countries at neonatal mortality rates of 30 or more @entity1 per 1000 livebirths. INTERPRETATION: Our findings show that the seemingly modest mortality reductions achieved by a newborn home-visit strategy might in fact be cost effective. In Ghana, such strategies are also likely to be affordable. Our findings support recommendations from WHO and UNICEF that @entity2 . FUNDING: The Bill _ Melinda Gates Foundation, UK Department for International Development, WHO.

title: Cost and XXXX : findings from the Newhints cluster-randomised controlled trial in rural Ghana.

answer: @entity4


abstract: AIMS: Cardiovascular (CV)-related hospitalization has been used as a surrogate endpoint for mortality in recent treatment studies on @entity2 ( @entity2 ), but our understanding of the relationship between CV-related hospitalization and @entity1 is incomplete. We aimed to investigate whether CV-related hospitalization is an independent risk factor and suitable as a surrogate endpoint for @entity1 in clinical studies of @entity0 with @entity2 . METHOD AND RESULTS: All 2912 @entity0 with a diagnosis of @entity2 in 2002 at one of Sweden's largest hospitals were studied for 6.5 years using information about medication from the local medical records. In a sub-study of the last 2.5 years of the study period, we used detailed information about medication from the new National Prescription Register. Information about diagnoses, hospitalizations, and deaths was obtained from national registries. @entity0 who were re-admitted to hospital with a CV diagnosis within the first 3 months had higher mortality than those who were not (15.6 vs. 9.3 deaths per 100 @entity0 -years at risk, P < 0.0001). Those who spent >2% of their time-at-risk in hospital with a CV diagnosis had higher mortality than those who had spent less time in hospital (36.0 vs. 8.2 deaths per 100 @entity0 years, P < 0.0001). After adjustment for co-factors, mortality was still higher for @entity0 who had been re-hospitalized for CV disease within 3 months than for those who had not [hazard ratio (HR) = 1.36; 95% confidence interval (CI) = 1.18-1.57]. When analyses were performed on @entity0 who had survived for 3 years since inclusion, and with the use of detailed information about the exposure to medication, the association between CV-related hospitalization and @entity1 was highly significant (HR 2.69, CI 1.96-3.68). These results were virtually unchanged after propensity score matching, which was done in order to adjust further for residual unidentified confounding. CONCLUSION: CV-related hospitalization is a marker for @entity0 who are at increased risk of @entity1 , and may be used as a valid surrogate endpoint in studies of @entity2 .

title: Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of @entity2 : report from the Stockholm Cohort Study of XXXX .

answer: @entity2


abstract: AIMS: Cardiovascular (CV)-related hospitalization has been used as a surrogate endpoint for mortality in recent treatment studies on @entity2 ( @entity2 ), but our understanding of the relationship between CV-related hospitalization and @entity1 is incomplete. We aimed to investigate whether CV-related hospitalization is an independent risk factor and suitable as a surrogate endpoint for @entity1 in clinical studies of @entity0 with @entity2 . METHOD AND RESULTS: All 2912 @entity0 with a diagnosis of @entity2 in 2002 at one of Sweden's largest hospitals were studied for 6.5 years using information about medication from the local medical records. In a sub-study of the last 2.5 years of the study period, we used detailed information about medication from the new National Prescription Register. Information about diagnoses, hospitalizations, and deaths was obtained from national registries. @entity0 who were re-admitted to hospital with a CV diagnosis within the first 3 months had higher mortality than those who were not (15.6 vs. 9.3 deaths per 100 @entity0 -years at risk, P < 0.0001). Those who spent >2% of their time-at-risk in hospital with a CV diagnosis had higher mortality than those who had spent less time in hospital (36.0 vs. 8.2 deaths per 100 @entity0 years, P < 0.0001). After adjustment for co-factors, mortality was still higher for @entity0 who had been re-hospitalized for CV disease within 3 months than for those who had not [hazard ratio (HR) = 1.36; 95% confidence interval (CI) = 1.18-1.57]. When analyses were performed on @entity0 who had survived for 3 years since inclusion, and with the use of detailed information about the exposure to medication, the association between CV-related hospitalization and @entity1 was highly significant (HR 2.69, CI 1.96-3.68). These results were virtually unchanged after propensity score matching, which was done in order to adjust further for residual unidentified confounding. CONCLUSION: CV-related hospitalization is a marker for @entity0 who are at increased risk of @entity1 , and may be used as a valid surrogate endpoint in studies of @entity2 .

title: Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of XXXX : report from the Stockholm Cohort Study of @entity2 .

answer: @entity2


abstract: Acute @entity4 is highly uncommon in neonates. Approximately 100 cases have been reported in the literature. @entity3 and prematurity are important predisposing factors. Diagnosis is based on clinical signs. White blood cell count and parotid ultrasonography are useful. The most commonly isolated causative organism is @entity2 . Initial treatment consists of antistaphylococcal empiric antimicrobial therapy for 7-10 days. The prognosis is good. The illness is not usually associated with recurrences. We describe two 12-day-old newborn @entity0 who presented with fever, unilateral swelling of the parotid region with erythema, warmness and @entity1 , and purulent discharge from Stensen's duct. We also provide a literature review.

title: [Neonatal acute XXXX ].

answer: @entity4


abstract: The influence of pretreatment with @entity3 [cytochrome P450 3A (CYP3A) + @entity6 ( @entity6 ) inhibitor], @entity4 (selective @entity6 inhibitor) and @entity1 (CYP3A + @entity6 inducer) on oral @entity2 pharmacokinetics and pharmacodynamics was investigated in experimental @entity0 . Seven beagles were used in a four-way crossover design. @entity5 was administered orally (2.5 mg/kg) alone (control group CON) or after pretreatment with @entity3 (group KETO), @entity4 (group ELA) or @entity1 (group RIF). @entity2 plasma concentrations were analysed by liquid chromatography-tandem mass spectrometry. Sedation scores (none, mild, moderate or severe) were evaluated subjectively. @entity0 were significantly (P < 0.05) more sedated after @entity3 pretreatment. There were no significant differences between group CON and the other pretreatment groups in pharmacokinetic parameters taking both sexes into account. Sex differences were apparent in some pharmacokinetic parameters of @entity2 . The area under the plasma concentration time curve (AUC(0-   ) ) was significantly higher, and the total body clearance was significantly lower in male compared to female @entity0 in all treatment groups. @entity3 , @entity1 and @entity4 pretreatment had no significant effects on @entity2 pharmacokinetics, although @entity0 in the @entity3 group showed higher sedation scores.

title: The influence of modulation of XXXX and/or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered @entity2 in @entity0 .

answer: @entity6


abstract: The influence of pretreatment with @entity3 [cytochrome P450 3A (CYP3A) + @entity6 ( @entity6 ) inhibitor], @entity4 (selective @entity6 inhibitor) and @entity1 (CYP3A + @entity6 inducer) on oral @entity2 pharmacokinetics and pharmacodynamics was investigated in experimental @entity0 . Seven beagles were used in a four-way crossover design. @entity5 was administered orally (2.5 mg/kg) alone (control group CON) or after pretreatment with @entity3 (group KETO), @entity4 (group ELA) or @entity1 (group RIF). @entity2 plasma concentrations were analysed by liquid chromatography-tandem mass spectrometry. Sedation scores (none, mild, moderate or severe) were evaluated subjectively. @entity0 were significantly (P < 0.05) more sedated after @entity3 pretreatment. There were no significant differences between group CON and the other pretreatment groups in pharmacokinetic parameters taking both sexes into account. Sex differences were apparent in some pharmacokinetic parameters of @entity2 . The area under the plasma concentration time curve (AUC(0-   ) ) was significantly higher, and the total body clearance was significantly lower in male compared to female @entity0 in all treatment groups. @entity3 , @entity1 and @entity4 pretreatment had no significant effects on @entity2 pharmacokinetics, although @entity0 in the @entity3 group showed higher sedation scores.

title: The influence of modulation of @entity6 and/or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered XXXX in @entity0 .

answer: @entity2


abstract: The influence of pretreatment with @entity3 [cytochrome P450 3A (CYP3A) + @entity6 ( @entity6 ) inhibitor], @entity4 (selective @entity6 inhibitor) and @entity1 (CYP3A + @entity6 inducer) on oral @entity2 pharmacokinetics and pharmacodynamics was investigated in experimental @entity0 . Seven beagles were used in a four-way crossover design. @entity5 was administered orally (2.5 mg/kg) alone (control group CON) or after pretreatment with @entity3 (group KETO), @entity4 (group ELA) or @entity1 (group RIF). @entity2 plasma concentrations were analysed by liquid chromatography-tandem mass spectrometry. Sedation scores (none, mild, moderate or severe) were evaluated subjectively. @entity0 were significantly (P < 0.05) more sedated after @entity3 pretreatment. There were no significant differences between group CON and the other pretreatment groups in pharmacokinetic parameters taking both sexes into account. Sex differences were apparent in some pharmacokinetic parameters of @entity2 . The area under the plasma concentration time curve (AUC(0-   ) ) was significantly higher, and the total body clearance was significantly lower in male compared to female @entity0 in all treatment groups. @entity3 , @entity1 and @entity4 pretreatment had no significant effects on @entity2 pharmacokinetics, although @entity0 in the @entity3 group showed higher sedation scores.

title: The influence of modulation of @entity6 and/or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered @entity2 in XXXX .

answer: @entity0


abstract: BACKGROUND: Keloids and @entity4 ( @entity4 ) affect 4.5-16% of the population. Thus far, the different approaches of keloid treatment are not very efficient, with a 50% relapse rate and many ongoing researches are looking for simple, safe and more efficient therapeutic methods. @entity2 is an immunomodulator that could be useful in treating keloid. OBJECTIVES: The objective of this study is to evaluate the effectiveness of @entity2 in inhibiting @entity4 formation on @entity1 ' ears model and to check optical skin spectroscopy in tissue characterization. METHODS: Our study was carried out on 20 New-Zealand female white @entity1 . @entity4 were obtained by wounding @entity1 ' ear. These wounds were treated with intradermal injections of @entity2 (0.2-0.5 mg/cm(2)) or a vehicule. The assessment of treatment efficacy was performed by clinical examinations, histological assay and skin spectrometry. RESULTS: @entity2 did not induce general or local side-effects. The scar elevation index in treated subjects was half less than that of the untreated ones. Furthermore, dermal thickness and inflammatory cellular density were both significantly smaller for treated scars than for the control ones. In vivo optical skin spectroscopy can characterize @entity3 and normal skin with high sensibility and specificity. CONCLUSION: Intradermal injection of @entity2 at 0.5 mg/cm(2) is an efficient way to prevent @entity4 in our experiment model and its tolerance is correct. Optical spectroscopy could be a good non-invasive tool to evaluate @entity4 treatment. These promising results might be proposed for @entity0 suffering from keloid.

title: Intradermal @entity2 prevent @entity3 in a XXXX ear model: a clinical, histological and spectroscopical analysis.

answer: @entity1


abstract: BACKGROUND: Keloids and @entity4 ( @entity4 ) affect 4.5-16% of the population. Thus far, the different approaches of keloid treatment are not very efficient, with a 50% relapse rate and many ongoing researches are looking for simple, safe and more efficient therapeutic methods. @entity2 is an immunomodulator that could be useful in treating keloid. OBJECTIVES: The objective of this study is to evaluate the effectiveness of @entity2 in inhibiting @entity4 formation on @entity1 ' ears model and to check optical skin spectroscopy in tissue characterization. METHODS: Our study was carried out on 20 New-Zealand female white @entity1 . @entity4 were obtained by wounding @entity1 ' ear. These wounds were treated with intradermal injections of @entity2 (0.2-0.5 mg/cm(2)) or a vehicule. The assessment of treatment efficacy was performed by clinical examinations, histological assay and skin spectrometry. RESULTS: @entity2 did not induce general or local side-effects. The scar elevation index in treated subjects was half less than that of the untreated ones. Furthermore, dermal thickness and inflammatory cellular density were both significantly smaller for treated scars than for the control ones. In vivo optical skin spectroscopy can characterize @entity3 and normal skin with high sensibility and specificity. CONCLUSION: Intradermal injection of @entity2 at 0.5 mg/cm(2) is an efficient way to prevent @entity4 in our experiment model and its tolerance is correct. Optical spectroscopy could be a good non-invasive tool to evaluate @entity4 treatment. These promising results might be proposed for @entity0 suffering from keloid.

title: Intradermal XXXX prevent @entity3 in a @entity1 ear model: a clinical, histological and spectroscopical analysis.

answer: @entity2


abstract: BACKGROUND: Keloids and @entity4 ( @entity4 ) affect 4.5-16% of the population. Thus far, the different approaches of keloid treatment are not very efficient, with a 50% relapse rate and many ongoing researches are looking for simple, safe and more efficient therapeutic methods. @entity2 is an immunomodulator that could be useful in treating keloid. OBJECTIVES: The objective of this study is to evaluate the effectiveness of @entity2 in inhibiting @entity4 formation on @entity1 ' ears model and to check optical skin spectroscopy in tissue characterization. METHODS: Our study was carried out on 20 New-Zealand female white @entity1 . @entity4 were obtained by wounding @entity1 ' ear. These wounds were treated with intradermal injections of @entity2 (0.2-0.5 mg/cm(2)) or a vehicule. The assessment of treatment efficacy was performed by clinical examinations, histological assay and skin spectrometry. RESULTS: @entity2 did not induce general or local side-effects. The scar elevation index in treated subjects was half less than that of the untreated ones. Furthermore, dermal thickness and inflammatory cellular density were both significantly smaller for treated scars than for the control ones. In vivo optical skin spectroscopy can characterize @entity3 and normal skin with high sensibility and specificity. CONCLUSION: Intradermal injection of @entity2 at 0.5 mg/cm(2) is an efficient way to prevent @entity4 in our experiment model and its tolerance is correct. Optical spectroscopy could be a good non-invasive tool to evaluate @entity4 treatment. These promising results might be proposed for @entity0 suffering from keloid.

title: Intradermal @entity2 prevent XXXX in a @entity1 ear model: a clinical, histological and spectroscopical analysis.

answer: @entity3


abstract: PURPOSE: This article gives an overview of the possibilities of conventional radiography in the diagnosis of @entity0 of the small intestine and colon. MATERIAL AND METHODS: For more than 25 years we examine the small bowel employing enteroclysis with barium and methylcellulose and the colon with the usual double-contrast method. In the last 152 months 1560 small bowel enemas were performed. In the last 40 months 410 examinations of the colon were performed. RESULTS: There is a thirty percent decrease in enteroclysis examinations within the past 5 years,however, the rate of examinations with positive results increased from 46 to 57%. The proportion of the inflammatory small intestinal diseases (not only @entity1 ) remained constant with 18%.Concerning the examinations of the colon for @entity2 we confirmed the diagnosis in seven cases. The radiation exposure for the enteroclysis in inflammatory diseases was 7 @entity3 , for colon examinations 14 @entity3 . CONCLUSION: Barium examinations, especially of the stomach and colon are decreasing in frequency. Therefore the art of performance and interpretation might get lost.Enteroclysis, however, is still the method of reference for the other imaging methods. The advantages compared to the other imaging methods are the excellent presentation of the details of the mucosal surface and the observation of functional disorders.

title: [Barium examinations of the small intestine and the XXXX ].

answer: @entity0


abstract: BACKGROUND: "High risk" @entity5 strains are the causative agents of the vast majority of @entity3 of the uterine cervix. In these @entity1 , the physical integration of the HPV genome is a frequent, though not invariable occurrence, but the constitutive expression of the E6 and E7 viral genes is always observed, suggesting key roles for the E6 and E7 oncoproteins in the process of malignant transformation. The "intracellular antibody" technology using recombinant antibodies in single-chain format offers the possibility of targeting a protein in its intracellular environment even at the level of definite domains thus representing a valuable strategy to "knock out" the function of specific proteins. METHODS: In this study, we investigate the in vitro activity of two single-chain antibody fragments directed against the "high-risk" @entity6 E7 oncoprotein, @entity7 43M2 and @entity7 51. These scFvs were expressed by retroviral system in different cell compartments of the @entity6 -positive @entity0 cells, and cell proliferation was analyzed by Colony Formation Assay and EZ4U assay. The binding of these scFvs to E7, and their possible interference with the interaction between E7 and its main target, the @entity1 suppressor @entity4 protein, were then investigated by immunoassays, PepSet    technology and Surface Plasmon Resonance. RESULTS: The expression of the two scFvs in the nucleus and the endoplasmic reticulum of @entity0 cells resulted in the selective growth inhibition of these cells. Analysis of binding showed that both scFvs bind E7 via distinct but overlapping epitopes not corresponding to the @entity4 binding site. Nevertheless, the binding of @entity7 43M2 to E7 was inhibited by @entity4 in a non-competitive manner. CONCLUSIONS: Based on the overall results, the observed inhibition of HPV-positive @entity0 cells proliferation could be ascribed to an interaction between @entity7 and E7, involving non- @entity4 targets. The study paves the way for the employment of specific scFvs in immunotherapeutic approaches against the @entity2 .

title: Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in XXXX -positive cells.

answer: @entity6


abstract: After operative correction of @entity8 , @entity0 continue to have excess @entity1 , including manifestations of @entity5 . Previous morphologic studies support the concept of direct hypertensive @entity7 in these @entity0 . To determine whether abnormalities of myocardial perfusion were present in an asymptomatic group of @entity0 with @entity8 repair, 18 @entity0 and 9 @entity0 with a mean age of 26 years (range 19 to 41) were studied between 2 and 25 years after operative correction. Stress electrocardiography and quantitative thallium imaging by a circumferential profile technique were used. These @entity0 were compared with a normal group, statistically defined as having a less than 1% prevalence of significant obstructive @entity3 . The @entity2 group demonstrated a @entity9 redistribution in each view analyzed. As compared with findings in the control subjects, thallium washout in the anterior view (41.9 versus 48.6%, p = 0.02) and left anterior oblique projection (40.5 versus 48.2%, p = 0.007) was significantly diminished. Although the @entity2 group had a lower @entity10 redistribution rate in the lateral view (41.4 versus 46.3%, p = 0.09) this difference did not reach statistical significance because of the intrinsic variability of this projection. Plots of the median percent thallium washout revealed independence from circumferential profile angle, indicating @entity6 in perfusion. No correlation between clinical variables and thallium kinetics could be established, suggesting marked individual variability in the development of this @entity4 . The observation of abnormal thallium kinetics in @entity0 with @entity8 repair may have consequences for long-term follow-up and therapy.

title: Abnormal thallium kinetics in XXXX of the aorta: evidence for diffuse hypertension-induced vascular pathology.

answer: @entity2


abstract: BACKGROUND: Several studies have reported an association between @entity6 and @entity2 although the cause/effect relationship is still controversial. CASE REPORT: In this paper we report the case of a 38-year-old female who first presented with a clinical history of @entity6 . Ultrasound examination showed a diffuse thyroid irregularity more pronounced in the right lobe. FNAC (Fine Needle Aspiration Cytology) was performed in this area, and the cytological diagnosis was " @entity6 ". The @entity0 underwent clinical follow-up. Two years later, an ultrasound examination showed a nodular lump in the area previously aspirated. A new FNAC evidenced a @entity8 . Therefore, the @entity0 underwent surgery. The histological diagnosis was " @entity3 ". CONCLUSION: In the present case, the clinical and ultrasound history suggest the development of a malignant lesion strictly related to @entity4 , as previously reported by other studies on @entity5 . A cause-effect relationship between @entity6 and @entity1 is still a matter of controversy. Therefore, @entity0 suffering from @entity7 require a careful follow-up and, in case of nodules development, FNAC is recommended.

title: XXXX : incidental association? A case report.

answer: @entity2


abstract: @entity6 (SCC) accounts for about 4% of all gynaecological @entity2 . It has an incidence of about 1.8 per 100,000. However, after the age of 75 the incidence of @entity5 peaks at approximately 20 per 100,000, making it as common as @entity10 . Benign and pre- @entity2 can be broadly divided into non-neoplastic epithelial disorders of the vulva (NNEDV), @entity13 ( @entity13 ) and @entity12 ( @entity12 ). NNEDV lesions include @entity11 ( @entity11 ) and @entity9 ( @entity9 ). To date no solid prognostic tools are available to predict which pre- @entity2 will progress to SCC. About 4.5% of @entity0 develop SCC following a history of @entity11 and ca. 4% of treated @entity14 go on to become vulvar SCC. In @entity12 , 28% of @entity0 have an underlying @entity2 . Angiogenesis, the development of new blood vessels from existing vasculature, is an essential component of solid @entity2 growth and @entity1 . Several angiogenic factors are expressed by many @entity2 , suggesting that @entity2 promote their own vascularisation by activating the host endothelium. This review follows the progress of research in angiogenesis in @entity14 as assessed by a variety of methods, such as in situ hybridisation (ISH), microvessel density measurements (MVD), immunohistochemically-detected angiogenic growth factor expression, including @entity3 ( @entity3 ) and platelet-derived endothelial cell growth factor/ @entity7 phosphorylase ( @entity8 /TP), and serum concentrations of @entity3 . Thus, the potential of angiogenesis as a prognostic and predictive tool for identifying which pre-malignant lesions could progress to SCC is discussed. A relatively high MVD and strong @entity3 expression may serve as prognostic indicators of survival in invasive SCC. MVD and @entity3 expression are also predictive factors in identifying which @entity14 are more likely to become invasive. However @entity3 is not a predictive marker in cases of @entity11 likely to progress to @entity5 . The expression of @entity8 /TP in all types of lesions tested prevents its use as a prognostic tool, unlike @entity3 . However, @entity8 /TP is involved in @entity12 pathogenesis, but is not a marker of the malignant progression of @entity12 . In @entity12 , @entity3 was not expressed even in those cases associated with invasive disease. Serum concentrations of @entity3 play a functional role in @entity4 . Although associated with impaired disease-free and overall survival, pre-treatment serum concentrations of @entity3 are not an independent predictor of outcome in @entity0 with @entity2 . These studies suggest that further angiogenic research will be important in both the therapy and prognosis of malignant and pre-malignant @entity14 .

title: Angiogenesis in benign, pre-malignant and XXXX .

answer: @entity2


abstract: BACKGROUND: Intravesical treatment with @entity5 ( @entity6 ) leads to a complete response rate of around 40% in superficial @entity2 ( @entity8 ). In order to determine in advance which @entity0 will fail to respond, we describe a study assessing the feasibility of applying the @entity4 assay to test the chemosensitivity of samples from @entity0 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity0 , 23 of which were suitable for the @entity4 assay (16 primary @entity1 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity6 between @entity0 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity1 stage or grade or the treatment status of the @entity0 in this small data set. @entity7 status and @entity3 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity6 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity6 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity4 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity6 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.

title: Ex vivo chemosensitivity to XXXX in @entity2 and its relationship with @entity7 and apoptotic factors.

answer: @entity5


abstract: BACKGROUND: Intravesical treatment with @entity5 ( @entity6 ) leads to a complete response rate of around 40% in superficial @entity2 ( @entity8 ). In order to determine in advance which @entity0 will fail to respond, we describe a study assessing the feasibility of applying the @entity4 assay to test the chemosensitivity of samples from @entity0 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity0 , 23 of which were suitable for the @entity4 assay (16 primary @entity1 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity6 between @entity0 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity1 stage or grade or the treatment status of the @entity0 in this small data set. @entity7 status and @entity3 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity6 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity6 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity4 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity6 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.

title: Ex vivo chemosensitivity to @entity5 in XXXX and its relationship with @entity7 and apoptotic factors.

answer: @entity2


abstract: BACKGROUND: Intravesical treatment with @entity5 ( @entity6 ) leads to a complete response rate of around 40% in superficial @entity2 ( @entity8 ). In order to determine in advance which @entity0 will fail to respond, we describe a study assessing the feasibility of applying the @entity4 assay to test the chemosensitivity of samples from @entity0 with this disease. MATERIALS AND METHODS: TURBT or biopsy samples were received from 27 @entity0 , 23 of which were suitable for the @entity4 assay (16 primary @entity1 and 7 recurrences). RESULTS: The success rate of the assay was 91%. There was a marked variation in the effect of @entity6 between @entity0 with a > 50-fold range in LC50 values (drug concentration required to kill 50% of cells) from 2.99- > 150 microM with a median value of 22.4 microM. We were unable to determine any overall correlation between chemosensitivity and @entity1 stage or grade or the treatment status of the @entity0 in this small data set. @entity7 status and @entity3 levels were assessed on these samples using immunohistochemistry but there did not appear to be any relationship between either of these parameters and @entity6 resistance. Apoptotic counts and mitotic counts were also measured but, whilst these appeared to correlate with grade (p < 0.01), there was no overall significant relationship established with @entity6 chemosensitivity. CONCLUSION: This study suggests that it is possible to use the @entity4 assay for chemosensitivity testing in TCCs. Despite a lack of overall correlation between ex vivo @entity6 resistance and the conventional prognostic factors tested, further studies are warranted in a larger data set to test the ability of this technique to predict clinical outcome in this disease.

title: Ex vivo chemosensitivity to @entity5 in @entity2 and its relationship with XXXX and apoptotic factors.

answer: @entity7


abstract: We report six @entity0 with @entity2 in whom @entity4 was prominent at diagnosis and who improved with dietary therapy. Joint @entity3 preceded diagnosis by up to three years in five @entity0 and 15 years in one @entity0 . Joints most commonly involved were lumbar spine, hips, and knees (four cases). In three cases there were no bowel symptoms. All were seronegative. X-rays were abnormal in two cases. HLA-type A1, B8, @entity7 was present in five and B27 in two @entity0 . Circulating immune complexes showed no consistent pattern before or after treatment. @entity2 was diagnosed in all @entity0 by jejunal biopsy, and joint symptoms in all responded to a gluten-free diet. Gluten challenge (for up to three weeks) failed to provoke @entity4 in three @entity0 tested. In a separate study of 160 treated coeliac @entity0 attending regular follow up no @entity4 attributable to @entity2 and no @entity6 was identified, though in a control group of 100 @entity0 with @entity1 the expected incidence of seronegative @entity4 (23%) and @entity6 (5%) was found (p less than 0.01). @entity4 appears to be a rare manifestation of @entity2 . This relationship may provide important clues to the role of gastrointestinal antigens in @entity5 .

title: XXXX and @entity2 .

answer: @entity4


abstract: We report six @entity0 with @entity2 in whom @entity4 was prominent at diagnosis and who improved with dietary therapy. Joint @entity3 preceded diagnosis by up to three years in five @entity0 and 15 years in one @entity0 . Joints most commonly involved were lumbar spine, hips, and knees (four cases). In three cases there were no bowel symptoms. All were seronegative. X-rays were abnormal in two cases. HLA-type A1, B8, @entity7 was present in five and B27 in two @entity0 . Circulating immune complexes showed no consistent pattern before or after treatment. @entity2 was diagnosed in all @entity0 by jejunal biopsy, and joint symptoms in all responded to a gluten-free diet. Gluten challenge (for up to three weeks) failed to provoke @entity4 in three @entity0 tested. In a separate study of 160 treated coeliac @entity0 attending regular follow up no @entity4 attributable to @entity2 and no @entity6 was identified, though in a control group of 100 @entity0 with @entity1 the expected incidence of seronegative @entity4 (23%) and @entity6 (5%) was found (p less than 0.01). @entity4 appears to be a rare manifestation of @entity2 . This relationship may provide important clues to the role of gastrointestinal antigens in @entity5 .

title: @entity4 and XXXX .

answer: @entity2


abstract: @entity10 is an @entity1 of squamous epithelium that results in @entity9 of the skin after minor @entity2 . Although severe @entity6 of the skin is the most common and obvious complication of the disease, esophageal @entity6 with formation of long strictures may also develop. In two affected siblings, such esophageal strictures occurred and progressed in severity to degrees necessitating esophageal replacement. Each received a preoperative period of total parenteral nutrition, which was continued into the postoperative period. In one, an isoperistaltic segment of right colon was placed substernally in a single stage procedure. In the other, a substernal reversed gastric tube was constructed, also in a single stage. This latter procedure was shorter and technically simpler than the colon interposition. The early postoperative courses in both were complicated by cervical @entity3 , which sealed spontaneously during a period of parenteral nutrition and @entity8 . Both subsequently developed cervical @entity4 . These were successfully managed by dilatations, and both @entity0 are now tolerating a solid diet. Neither @entity0 experienced problems from endotracheal intubation. Epithelial loss occurred in the skin adjacent to the surgical incision but healed quickly with topical @entity5 therapy. This report confirms previous reports that esophageal replacement is well tolerated by @entity0 with @entity7 and suggests that the reversed gastric tube technique, not previously reported used for this disease, may be preferable to colon esophagoplasty.

title: Esophageal replacement in two siblings with XXXX .

answer: @entity7


abstract: @entity2 and @entity3 metabolism abnormalities are frequent in @entity5 @entity0 and the role of @entity1 in such ionic perturbations may have been overlooked. The authors herein report the complete primary structure of a Bence Jones Vkappal light chain responsible for @entity1 with increased @entity7 . Plasma and serum biochemical evaluations indicated a proximal tubular dysfunction mainly manifested as @entity8 and @entity3 loss. The study of a kidney biopsy showed @entity1 with numerous @entity5 casts and peculiar features of the proximal tubular cells, which carried numerous phagolysosomal inclusions with occasional crystalline periodic striation. The nephrotoxic light chain primary structure was deduced from the bone marrow monoclonal plasma cells RNA. The kappal sequence was highly homologous to kappa chains previously characterized in @entity0 with @entity6 . It was related to the Vkappal subgroup and was composed of a variable segment encoded by the O8/O18 germline gene rearranged to Jkappa4. The primary sequence presented unusual features restricted to the variable region, including substitutions of residues 28 and 31 in the complementary determining region 1 (CDR1) by @entity4 of different charge. An unusual conformation of the kappal domain, likely resulting from somatic hypermutation, could alter the catabolism of the protein after its internalization and result in the tubular cell dysfunction. Comparison with @entity6 studies suggests that Vkappal Bence Jones proteins may damage proximal tubular cells to an extent varying according to light chain (LC) sequence and structure, either leading to crystal formation and @entity6 or inducing partial inhibition of proximal tubule function.

title: A monoclonal V kappa l light chain responsible for XXXX .

answer: @entity1


abstract: The purpose of the study reported here was to further investigate a new method of estimating inbreeding in large, relatively isolated populations over historic times, as reported by Pattison (1999, 2001). The method is based on modeling the genealogical "paradox" and produces values of Pearl's coefficients of inbreeding as a function of time for any given population curve. In particular, this study demonstrates that the new method of estimating inbreeding may be used to examine the effect of unusual features in population curves on levels of inbreeding in that population. As an example, the medieval population "bump" that spans the 13th and 14th centuries in the population of Britain, which terminated abruptly with the outbreak of @entity1 in 1348 @entity0 , is examined. It is first assumed that the whole population was the adult (breeding) population, corresponding to minimum inbreeding. For this case it is found that, for distant generations, about 90% of the whole population occurs in any present-day British pedigree. This value compares favorably with the values of 85% and 80% reported by Wachter (1980) and Derrida et al. (1999, 2000), respectively. The population bump causes the curves for Pearl's coefficient, for minimum inbreeding, to have a plateau of about 96% over the period from about 1220 @entity0 to 1380 @entity0 . The effect of introducing a single known estimate of inbreeding into the model is to produce a more realistic situation where the adult (breeding) population is considerably less than the whole population. It is found that the maximum number of different ancestors in any generation, in the average British pedigree, is about 22900 individuals and occurs about 1220 @entity0 . More importantly, and possibly contrary to expectation, it is now found that the population bump had virtually no effect on the level of inbreeding.

title: Effect of the XXXX on inbreeding in 14th century Britain.

answer: @entity1


abstract: BACKGROUND: To summarize the preliminary experience on Iressa for refractory @entity7 ( @entity7 ). METHODS: Fifty-five @entity0 with @entity7 , who failed after surgery, radiotherapy, chemotherapy or combination of the above modalities, were registered in this clinical trail. Prior to Iressa, 50 @entity0 were in stage IV, and 5 in stage III. Iressa was administered orally at 250 mg, once a day until @entity2 progressed or severe @entity3 occured, which made @entity0 intolerable. The median time for administration of Iressa was 4 months. RESULTS: The @entity3 of Iressa was tolerable with 47% of @entity3 ( @entity9 ) and 2%-7% of @entity4 , @entity5 , @entity10 and @entity8 . Overall response rate was 20%. Different sites of distant metastases responded to Iressa in different ways with higher response rate for pulmonary disseminations. One quarter of @entity0 felt improvement of their symptoms over 2 weeks. Median survival time for entire group was 5 months (1-17 months). Median @entity6 ( @entity6 ) was 3.6 months. Survival at 6 months was 67%. Prognostic predictor, which could imply the outcome, was @entity3 with higher response rate and longer survival time ( P < 0.05), and no relationship with sex, histological types of @entity7 and distant @entity1 had been found. CONCLUSIONS: Iressa could be tolerated by refractory @entity7 @entity0 with acceptable side-effects, and have palliative effects.

title: [Iressa for refractory XXXX : A preliminary report].

answer: @entity7


abstract: BACKGROUND: @entity1 ( @entity1 ) is a metabolic bone illness that may complicate @entity5 ( @entity5 ). It can lead to devastating consequences because of low bone mass and @entity2 . PURPOSE: To study the @entity1 prevalence in a group of Brazilian @entity0 with @entity5 and the value of a @entity5 ( @entity5 ). METHODS: Retrospective study of celiac female @entity0 from a single University Center followed with bone densitometries. Results from densitometry made at first visit were compared with a second study after a median time of 5 years. During this period, @entity0 were submitted to a @entity5 according to orientations from special program training. @entity3 and @entity4 were prescribed to those @entity0 who did not reach the minimal daily requirement through diet. RESULTS: Forty-one celiac female @entity0 , mean age 46.1    14.8 years, were included. The prevalence of @entity6 at first visit was 56.1% and that of @entity1 29.2%. @entity1 was associated with longer disease duration (p = 0.01). The second densitometry was performed in a median time of 5 years (range 1 to 13 years) and disclosed 58.9% @entity6 and 28.2% @entity1 . The @entity5 improved bone mass, mainly at (of) spine (comparison of T score with p = 0.03 and of bone mass in g/cm2 with p = 0.02), but it was not sufficient to reduce the number of @entity8 (p = 0.9) and @entity7 @entity0 (p = 0.4). During the follow up period 25% of @entity7 @entity0 developed low impact @entity2 . CONCLUSION: Bone health is notably impaired at baseline in @entity5 @entity0 , especially in those with a diagnostic delay. A @entity5 modestly improved bone mass density with low impact @entity2 occurring in one third of @entity0 during the follow up period.

title: Impact of a gluten-free diet on bone mineral density in celiac XXXX .

answer: @entity0


abstract: PURPOSE: Infusion of a source of endothelial progenitor cells (EPC) into the @entity1 myocardium is emerging as a promising therapy for @entity1 , probably mediated by the formation of new blood vessels. Studies have shown that while the procedure is safe and feasible, efficacy results are contentious. The investigators hypothesized that the infusion of a combination cell product consisting of a source of EPC and mesenchymal stem cells (MSC) is safe and promotes the formation of more stable and mature blood vessels resulting in improved clinical outcomes. METHODS: Ten @entity0 with stable @entity3 (class III to IV) on maximal medical therapy were included. All @entity0 had >=  70% stenosis in at least one coronary artery, and none was considered a candidate for percutaneous coronary intervention or coronary artery bypass graft. End points were feasibility and safety of intracoronary infusion of the combination cell product and assessment of @entity2 , left ventricular ejection fraction (LVEF), and quality of life at 6 months postinfusion. RESULTS: Six months after cell infusion there were no adverse clinical events. Functional cardiac evaluation during the same period showed significant improvements in LVEF (average increase: 11%, P = .02) and @entity2 (average decrease: 1.8 fold, P = .02). Additionally, all @entity0 described significant improvements in quality of life. CONCLUSIONS: Despite the inherent limitations associated with a Phase I clinical trial, this study demonstrates that the intracoronary infusion of the combination cell product is feasible and safe and also insinuates that this form of therapy may be beneficial.

title: Combination stem cell therapy for the treatment of medically refractory XXXX : a Phase I study.

answer: @entity1


abstract: BACKGROUND: To evaluate the efficacy and safety of @entity4 in combination with @entity6 as first-line treatment of @entity0 with inoperable, locally advanced or metastatic @entity3 ( @entity3 ). @entity0 AND METHODS: Chemotherapy-naive @entity0 with stage IIIB and IV @entity3 , age < 75 years, performance status (WHO) 0-2, were enrolled onto the study. @entity4 was given at a dose of 100 mg/m2 over an 1-hour i.v. infusion. @entity6 dosed to an area under the time-concentration curve (AUC) of 6 mg/ml.minute, using the Calvert's formula, was administered over a 30-minute i.v. infusion. The regimen was repeated every 3 weeks. RESULTS: Thirty-eight @entity0 received a total of 155 chemotherapy cycles (median 4 cycles/ @entity0 ). All @entity0 were assessable for @entity2 and 34 for response. There was one (2.6%) complete and nine (23.7%) partial responses; in an intention-to-treat analysis the overall response rate was 26.6% (95% CI: 12.3%-40.3%). The median duration of response was 7 months (range: 3-29), the median time to @entity1 progression 7 months (range: 3.5-31), and the median overall survival 9 months (range: 0.5-31.5). The probability for 1-year survival was 44%. Grade 3-4 @entity5 was the main hematological @entity2 of the regimen occurring in 19 (50%) @entity0 . Four (10.5%) @entity5 episodes were complicated with fever but there was no septic death. Non-hematological @entity2 was generally mild. CONCLUSION: These results indicate that the @entity4 - @entity6 combination is a relatively active and well-tolerated front-line regimen for the treatment of @entity0 with advanced or metastatic @entity3 .

title: A multicenter phase II study of @entity4 and @entity6 combination as front-line treatment in advanced XXXX .

answer: @entity3


abstract: BACKGROUND: To evaluate the efficacy and safety of @entity4 in combination with @entity6 as first-line treatment of @entity0 with inoperable, locally advanced or metastatic @entity3 ( @entity3 ). @entity0 AND METHODS: Chemotherapy-naive @entity0 with stage IIIB and IV @entity3 , age < 75 years, performance status (WHO) 0-2, were enrolled onto the study. @entity4 was given at a dose of 100 mg/m2 over an 1-hour i.v. infusion. @entity6 dosed to an area under the time-concentration curve (AUC) of 6 mg/ml.minute, using the Calvert's formula, was administered over a 30-minute i.v. infusion. The regimen was repeated every 3 weeks. RESULTS: Thirty-eight @entity0 received a total of 155 chemotherapy cycles (median 4 cycles/ @entity0 ). All @entity0 were assessable for @entity2 and 34 for response. There was one (2.6%) complete and nine (23.7%) partial responses; in an intention-to-treat analysis the overall response rate was 26.6% (95% CI: 12.3%-40.3%). The median duration of response was 7 months (range: 3-29), the median time to @entity1 progression 7 months (range: 3.5-31), and the median overall survival 9 months (range: 0.5-31.5). The probability for 1-year survival was 44%. Grade 3-4 @entity5 was the main hematological @entity2 of the regimen occurring in 19 (50%) @entity0 . Four (10.5%) @entity5 episodes were complicated with fever but there was no septic death. Non-hematological @entity2 was generally mild. CONCLUSION: These results indicate that the @entity4 - @entity6 combination is a relatively active and well-tolerated front-line regimen for the treatment of @entity0 with advanced or metastatic @entity3 .

title: A multicenter phase II study of @entity4 and XXXX combination as front-line treatment in advanced @entity3 .

answer: @entity6


abstract: BACKGROUND: To evaluate the efficacy and safety of @entity4 in combination with @entity6 as first-line treatment of @entity0 with inoperable, locally advanced or metastatic @entity3 ( @entity3 ). @entity0 AND METHODS: Chemotherapy-naive @entity0 with stage IIIB and IV @entity3 , age < 75 years, performance status (WHO) 0-2, were enrolled onto the study. @entity4 was given at a dose of 100 mg/m2 over an 1-hour i.v. infusion. @entity6 dosed to an area under the time-concentration curve (AUC) of 6 mg/ml.minute, using the Calvert's formula, was administered over a 30-minute i.v. infusion. The regimen was repeated every 3 weeks. RESULTS: Thirty-eight @entity0 received a total of 155 chemotherapy cycles (median 4 cycles/ @entity0 ). All @entity0 were assessable for @entity2 and 34 for response. There was one (2.6%) complete and nine (23.7%) partial responses; in an intention-to-treat analysis the overall response rate was 26.6% (95% CI: 12.3%-40.3%). The median duration of response was 7 months (range: 3-29), the median time to @entity1 progression 7 months (range: 3.5-31), and the median overall survival 9 months (range: 0.5-31.5). The probability for 1-year survival was 44%. Grade 3-4 @entity5 was the main hematological @entity2 of the regimen occurring in 19 (50%) @entity0 . Four (10.5%) @entity5 episodes were complicated with fever but there was no septic death. Non-hematological @entity2 was generally mild. CONCLUSION: These results indicate that the @entity4 - @entity6 combination is a relatively active and well-tolerated front-line regimen for the treatment of @entity0 with advanced or metastatic @entity3 .

title: A multicenter phase II study of XXXX and @entity6 combination as front-line treatment in advanced @entity3 .

answer: @entity4


abstract: BACKGROUND: @entity0 with @entity3 ( @entity3 ) frequently present with typical @entity2 ; however a considerable proportion may present with atypical symptoms. OBJECTIVE: The purpose of this study was to evaluate the prognostic value of different presenting symptoms in @entity3 @entity0 . METHODS: Over a 5-month period in 2007, 6704 consecutive @entity0 presenting with @entity3 were enrolled and categorized into three groups according to their presenting symptom (typical @entity2 , atypical @entity2 , and @entity4 ). Data were collected from a prospective, multicenter, multinational, observational study from 6 countries. The baseline characteristics, therapy, and in-hospital outcomes were analyzed and compared in the three groups. RESULTS: In comparison to typical @entity2 , @entity0 with @entity1 or @entity4 were older and had more cardiovascular risk factors. These two groups were significantly less likely to receive evidence-based therapy and coronary angiography and suffered worse in-hospital outcomes. The mortality rates were 3%, 2.5%, and 6% in @entity0 presenting with typical, atypical @entity2 , and @entity4 , respectively. After adjustment for confounders, the absence of typical @entity2 was associated with higher mortality rate (odds ratio 2.0, 95% confidence intervals 1.29-2.75). CONCLUSIONS: Across @entity3 , @entity0 presenting without @entity2 were frequently underestimated, less well treated with evidence-based therapy, and had worse in-hospital outcomes. Clinical presentation of @entity3 may provide additional prognostic impact particularly in high-risk populations.

title: Atypical presentation of XXXX : a significant independent predictor of in-hospital mortality.

answer: @entity3


abstract: Perturbations in the normal sequence of ventricular activation can create regions of early and late activation, leading to @entity2 and areas of dyskinesis. Dyskinesis occurs across the left ventricular (LV) wall, and its presence may have important consequences on cardiac structure and function in normal and failing hearts. Acutely, dyskinesis can trigger @entity0 and, in the long term (6 wk and above), leads to LV remodeling. The mechanisms that trigger these changes are unknown. To gain further insight, we used a @entity1 model to evaluate transumural changes in myocardial function and @entity0 induced by epicardial LV pacing. The results indicate that 4 h of LV suprathreshold pacing resulted in a 30% local loss of endocardial thickening. Assessment of neutrophil infiltration showed a significant approximately fivefold increase in @entity4 activity in the epicardium versus the midwall/endocardium. @entity3 activity increased    2 fold in the epicardium and ROS generation increased    2.5-fold compared with the midwall/endocardium. To determine the effects that electrical current alone has on these end points, a group of animals was subjected to subthreshold pacing. Significant increases were observed only in epicardial @entity4 levels. Thus, the results indicate that transmural dyskinesis induced by suprathreshold epicardial LV activation triggers a localized epicardial inflammatory response, whereas subthreshold stimulation appears to solely induce the trapping of leucocytes. Suprathreshold pacing also induces a loss of endocardial function. These results may have important implications as to the nature of the mechanisms that trigger the inflammatory response and possibly long-term remodeling in the setting of dysynchrony.

title: Ventricular pacing-induced loss of contractile function and development of XXXX .

answer: @entity0


abstract: BACKGROUND: Torsion of the ovary is a rare but serious cause of gynecologic surgical emergency. Specific laboratory markers that support the preoperative diagnosis of @entity2 are not currently available in the clinical routine. The aim of this study was to investigate the diagnostic value of plasma D-dimer level as an early indicator of @entity2 in an experimental @entity1 @entity2 model. METHODS: Sixteen female adult @entity1 were used for this controlled experimental study. Eight @entity1 in the sham operation group (Group I) underwent a surgical procedure similar to Group II but the ovary was not occluded. In Group II (eight @entity1 ), a torsion model was created by using atraumatic vascular clips just above and below the right ovary for a 2-h period of @entity3 . Right ovaries were surgically removed at the end of the procedure in each group. Blood was sampled before and after operation to assess plasma D-dimer levels. The main outcome measure was ovarian histopathologic findings scores and plasma D-dimer levels. RESULTS: There was no significant difference in pre-operative plasma D-dimer levels (0.5963    0.2047 mg/l in Group I, 0.6344    0.1348 mg/l in Group II, P = 0.815, Mann-Whitney U-test). However, mean plasma D-dimer value for Group II was significantly higher than that in the control group (1.2267    0.3099 versus 0.6213    0.2346 mg/l, respectively, Mann-Whitney U-test, P < 0.001), following 2 h of @entity2 . Ovarian tissue damage scores were also statistically significantly different among groups. CONCLUSIONS: If the observations made in a @entity1 model are extended to @entity0 , plasma D-dimer measurement may be a valuable parameter in the early diagnosis of @entity2 .

title: Acute increase in plasma D-dimer level in XXXX : an experimental study.

answer: @entity2


abstract: OBJECTIVES: @entity0 can fulfil clinical criteria for remission, yet still have evidence of @entity5 detectable clinically and by ultrasound, and this is associated with structural damage. Stricter remission criteria may more accurately reflect true remission (no @entity5 ). This hypothesis was examined by studying @entity0 using more stringent thresholds for clinical remission and determining their levels of ultrasound @entity5 . METHODS: @entity4 @entity0 with a disease activity score in 28 joints (DAS28)  <=2.6 for at least 6 months were classified using standard and more stringent DAS28 and simplified disease activity index (SDAI) remission thresholds and the corresponding clinical and ultrasound imaging measures of @entity5 recorded. RESULTS: 128 @entity0 (all DAS28 <2.6, median DAS28 1.70) receiving either disease-modifying antirheumatic drugs alone (n=66) or with a @entity1 @entity3 factor blocker (n=62) were recruited. Of the 640 imaged joints, 5% had moderate or severe power Doppler (PD) activity, 8% were clinically swollen and 1% tender. In @entity0 fulfilling DAS28, American College of Rheumatology or SDAI remission criteria, moderate or severe PD activity was present in 21%, 15% and 19%, respectively. More stringent DAS28 and SDAI criteria reduced the mean number of swollen and @entity6 (p<0.001) but not the percentage of @entity0 with PD activity: 32 @entity0 had a DAS28 <1.17 but eight (25%) had significant PD activity. CONCLUSION: Using more stringent remission criteria resulted in reduced signs and symptoms of @entity2 , but the percentage of joints with PD activity was not reduced, even in those without signs or symptoms. These data suggest that clinical criteria are sufficiently insensitive to detect low but clinically relevant levels of @entity2 accurately.

title: Should imaging be a component of XXXX remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments.

answer: @entity4


abstract: @entity2 -peptide hydrogels have been developed in our laboratory as new synthetic extracellular matrices for regenerative medicine applications. In this work, we have expanded on our previously reported system and applied copolymerization of @entity1 ( @entity3 ) and @entity5 (VS)-functionalized @entity2 -peptide polymers via Michael-type addition for encapsulation and 3D culture of cells. Specifically, our aims were to (1) develop a novel hydrogel platform, which could be applied for encapsulating and culturing mesenchymal stem cells (MSCs) in a 3D environment, (2) characterize the tunable properties of the hydrogel, specifically, degradation, mechanical, and gel network properties, and (3) determine the biocompatibility of the @entity2 -peptide hydrogel material with MSCs. Hydrogel mechanical properties were tunable by varying the VS: @entity3 ratio (= 0.5, 1, or 2) as well as the pH (6, 7, or 8) of the cross-linking components. Stiffer gels were formed at VS: @entity3 = 1 and pH 6 or 7. Gels formed at pH 8 or with excess @entity3 (VS: @entity3 = 0.5) or VS (VS: @entity3 = 2) were significantly softer. @entity4 and VS: @entity3 ratio also had an effect on the degradation behavior of the VS: @entity3 gels, with higher cross-linking pH resulting in an accelerated loss of mass. On the basis of environmental scanning electron microscopy (ESEM) analysis and fluorescence microscopy, all hydrogels appeared to exhibit porous gel networks. MSCs cultured in monolayer and exposed to soluble @entity3 or VS copolymers (0.1-5 mg/mL) did not exhibit measurable @entity0 . In addition, MSCs were cultured in 3D for up to 14 days in vitro without deleterious effects on cell viability. In summary, we have established and characterized a tunable 3D @entity2 -peptide hybrid copolymer hydrogel platform for culturing MSCs. Future studies will focus on utilizing the hydrogel system for controlling the differentiation of MSCs.

title: Biodegradable and biocompatible synthetic XXXX -Peptide hydrogels for three-dimensional stem cell culture.

answer: @entity2


abstract: Cold-induced changes of gene expression and metabolism are critical for plants to survive freezing. Largely by changing gene expression, exposure to a period of non-freezing low temperatures increases plant tolerance to freezing-a phenomenon known as cold acclimation. Cold also induces rapid metabolic changes, which provide instant protection before temperature drops below freezing point. The molecular mechanisms for such rapid metabolic responses to cold remain largely unknown. Here, we use two-dimensional difference gel electrophoresis (2-D DIGE) analysis of sub-cellular fractions of @entity1 proteome coupled with spot identification by tandem mass spectrometry to identify early cold-responsive proteins in @entity1 . These proteins include four enzymes involved in starch degradation, three HSP100 proteins, several proteins in the @entity4 cycle, and @entity2 metabolism. Upon cold treatment, the @entity6 ( @entity6 ), a cytosolic transglucosidase metabolizing maltose to @entity0 , increased rapidly in the centrifugation pellet fraction and decreased in the soluble fraction. Consistent with cold-induced inactivation of @entity6 enzymatic activity, the @entity6 mutant showed increased freezing tolerance without affecting the C-repeat binding transcription factor (CBF) transcriptional pathway. These results support a model that cold-induced inactivation of @entity6 leads to rapid accumulation of @entity5 , which is a cold-induced compatible solute that protects cells from freezing damage. This study provides evidence for a key role of rapid post-translational regulation of @entity3 metabolic enzymes in plant protection against sudden temperature drop.

title: Proteomics analysis reveals post-translational mechanisms for cold-induced metabolic changes in XXXX .

answer: @entity1


abstract: A three-year-old male @entity0 was brought to our clinic by his family with the complaint of a non-healing wound with discharge on his forehead and the nasal region. He had a history of a fall one-year ago. The @entity0 had recurrent complaints of @entity1 and @entity5 following this @entity2 . He had undergone an operation with the pre-diagnosis of foreign body in soft tissue six months ago. However, no foreign body had been detected and the inflamed tissue had been excised and closed again. The @entity1 and purulent discharge in the region between nose and eye continued after this surgery. The @entity0 underwent an operation and a circular defect 0.5 cm in diameter was detected on the dorsum of the nasal bone and a @entity4 tract was found to have developed between this defect and the skin between the nose and the eye. A subcutaneous @entity6 without skin tissue was removed including the periosteum from the left part of forehead after excision of the @entity4 tract. The flap was transferred to the nasal dorsum and the component of the @entity6 including the periosteum was used for reconstruction of the nasal mucosa. The wound healed without any problems and no @entity4 or @entity3 developed again during the six-month follow-up.

title: A rare case of XXXX : nasocutaneous @entity4 .

answer: @entity4


abstract: A three-year-old male @entity0 was brought to our clinic by his family with the complaint of a non-healing wound with discharge on his forehead and the nasal region. He had a history of a fall one-year ago. The @entity0 had recurrent complaints of @entity1 and @entity5 following this @entity2 . He had undergone an operation with the pre-diagnosis of foreign body in soft tissue six months ago. However, no foreign body had been detected and the inflamed tissue had been excised and closed again. The @entity1 and purulent discharge in the region between nose and eye continued after this surgery. The @entity0 underwent an operation and a circular defect 0.5 cm in diameter was detected on the dorsum of the nasal bone and a @entity4 tract was found to have developed between this defect and the skin between the nose and the eye. A subcutaneous @entity6 without skin tissue was removed including the periosteum from the left part of forehead after excision of the @entity4 tract. The flap was transferred to the nasal dorsum and the component of the @entity6 including the periosteum was used for reconstruction of the nasal mucosa. The wound healed without any problems and no @entity4 or @entity3 developed again during the six-month follow-up.

title: A rare case of @entity4 : nasocutaneous XXXX .

answer: @entity4


abstract: The increased susceptibility of severely injured @entity0 to @entity4 and @entity3 from @entity5 has been attributed to abnormalities in cell-mediated immunity. The authors therefore assessed the relative number of peripheral blood T helper cells and T suppressor/cytotoxic cells and total T lymphocytes identified by the monoclonal antibodies (McA) OKT4, OKT8, and OKT3, respectively, in 25 @entity0 with burns from 5 to 85% total body surface area (TBSA) (mean: 40%) and 21 @entity0 with nonthermal injuries (mean Injury Severity Score (ISS): 21.4). @entity0 were compared to 21 healthy controls. Cells reacting with the @entity6 were detected by flow cytometry, which enabled the examination of a population of cells the size of T lymphocytes, excluding larger contaminating cells that might bind the McA. @entity0 with burns of 30% TBSA or greater had a significant reduction (p less than or equal to 0.05) in @entity1 + cells up to 50 days post-burn. Both septic and nonseptic burn @entity0 had reduced numbers of @entity1 + cells, as did @entity0 after nonthermal injury, suggesting that this reduction was due to the injury itself. @entity0 with smaller burns (less than 30% TBSA) as a group did not have reduced @entity1 + cells, whereas those with larger burns showed significant reductions in @entity1 + cells (P less than or equal to 0.05) at 0 to 5, 6 to 10, 11 to 20, 21 to 30, and 41 to 50 days post-burn. Seven burn @entity0 who became septic 10 days post-burn or later had significantly lower @entity1 + cells within 10 days of injury (mean: 33.75% +/- 7.4 SEM) than 10 @entity0 who remained free of @entity5 (mean: 42.2% +/- 5.4, p = 0.004). @entity0 with uncomplicated nonthermal injuries failed to show any significant reduction in @entity1 + cells. Following @entity2 , a reduction in @entity1 + cells was observed up to 10 days in @entity0 with burns less than 30% TBSA, and up to 20 days in @entity0 with larger burns. In both groups, at no time were increased @entity1 + cells found to correlate with clinical events. In @entity0 with nonthermal injury, @entity1 + cells generally remained near the normal range.

title: Changes in T lymphocyte subsets following injury. Assessment by flow cytometry and relationship to XXXX .

answer: @entity5


abstract: Forearm vascular responses to intra-arterial infusions of endothelium-dependent and -independent vasodilators have been thoroughly characterized in @entity0 . While the forearm is a well-established experimental model for studying @entity0 vascular function, it is of limited consequence to systemic cardiovascular control owing to its small muscle mass and blood flow requirements. In the present study we determined whether these responses could be generalized to the leg. Based upon blood pressure differences between the leg and arm during upright posture, we hypothesized that the responsiveness to endothelium-dependent vasodilators would be greater in the forearm than the leg. @entity3 (Q, ultrasound Doppler) at rest and during intra-arterial infusions of endothelium-dependent ( @entity1 and @entity5 ) and -independent ( @entity4 ) vasodilators were measured in eight healthy @entity0 (22-27 years old). Resting blood flows in the forearm before infusion of @entity1 , @entity5 or @entity4 were 25 +/- 4, 30 +/- 7 and 29 +/- 5 ml @entity2 ), respectively, and in the leg were 370 +/- 32, 409 +/- 62 and 330 +/- 30 ml @entity2 ), respectively. At the highest infusion rate of @entity1 (16 microg (100 ml tissue)(-1) @entity2 )) there was a greater (P < 0.05) increase in Q to the forearm (1864 +/- 476%) than to the leg (569 +/- 86%). Similarly, at the highest infusion rate of @entity5 (125 pg (100 ml tissue)(-1) @entity2 )) there was a greater (P < 0.05) increase in Q to the forearm (911 +/- 286%) than to the leg (243 +/- 58%). The responses to @entity4 (1 microg (100 ml tissue)(-1) @entity2 )) were also greater (P < 0.05) in the forearm (925 +/- 164%) than in the leg (326 +/- 65%). These data indicate that vascular responses to both endothelium-dependent and -independent vasodilator agents are blunted in the leg compared to the forearm.

title: Different vasodilator responses of XXXX arms and legs.

answer: @entity0


abstract: Results of cisternal CSF analyses of 77 @entity3 with primary @entity6 (1970 to 1984) were examined retrospectively. The types of primary @entity6 were @entity5 , @entity8 , @entity4 , @entity7 , and @entity9 . Fifty-three @entity3 had complete CSF analyses performed (total WBC count, total protein content, and pressure). Of these 53 CSF, 39.6% had a pattern of change consistent with current descriptions of CSF associated with @entity2 . Results of the remaining 60.4% of the 53 CSF were normal (9.4%) or had an atypical pattern of abnormality (50.9%). The CSF associated with @entity7 was unique in having CSF with a WBC count greater than 50 cells/microliter and a WBC differential count greater than 50% @entity10 ( @entity10 ) cells. Within the @entity7 group, a predominance of @entity10 cells in the CSF correlated with @entity1 or @entity10 cell infiltration of the @entity0 . Additional correlations between specific CSF characteristics and histologic features of the @entity0 could not be made. Statistical analysis of the 77 CSF revealed that the mean CSF total WBC count of the @entity9 group was significantly less than the mean WBC count of the @entity8 group and the @entity7 group. The mean CSF total protein contents of the @entity5 group and the @entity7 group were significantly less than the mean protein of the @entity8 group. The mean CSF pressure of the @entity0 groups was not significantly different. For all 77 @entity0 , the most common abnormality was an increased total protein content (69.4%); the least common abnormality was an increased total WBC count (41.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Characteristics of cisternal cerebrospinal fluid associated with primary XXXX in the @entity3 : a retrospective study.

answer: @entity6


abstract: Results of cisternal CSF analyses of 77 @entity3 with primary @entity6 (1970 to 1984) were examined retrospectively. The types of primary @entity6 were @entity5 , @entity8 , @entity4 , @entity7 , and @entity9 . Fifty-three @entity3 had complete CSF analyses performed (total WBC count, total protein content, and pressure). Of these 53 CSF, 39.6% had a pattern of change consistent with current descriptions of CSF associated with @entity2 . Results of the remaining 60.4% of the 53 CSF were normal (9.4%) or had an atypical pattern of abnormality (50.9%). The CSF associated with @entity7 was unique in having CSF with a WBC count greater than 50 cells/microliter and a WBC differential count greater than 50% @entity10 ( @entity10 ) cells. Within the @entity7 group, a predominance of @entity10 cells in the CSF correlated with @entity1 or @entity10 cell infiltration of the @entity0 . Additional correlations between specific CSF characteristics and histologic features of the @entity0 could not be made. Statistical analysis of the 77 CSF revealed that the mean CSF total WBC count of the @entity9 group was significantly less than the mean WBC count of the @entity8 group and the @entity7 group. The mean CSF total protein contents of the @entity5 group and the @entity7 group were significantly less than the mean protein of the @entity8 group. The mean CSF pressure of the @entity0 groups was not significantly different. For all 77 @entity0 , the most common abnormality was an increased total protein content (69.4%); the least common abnormality was an increased total WBC count (41.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Characteristics of cisternal cerebrospinal fluid associated with primary @entity6 in the XXXX : a retrospective study.

answer: @entity3


abstract: PURPOSE: To evaluate initial experience with radiofrequency (RF) ablation of @entity11 . MATERIALS AND METHODS: Thirteen adrenal masses in 12 @entity0 (bilateral @entity2 in one @entity0 ) were treated with computed tomography (CT)-guided percutaneous RF ablation. Eleven adrenal lesions were @entity2 (five from @entity1 , four from @entity8 , and two from @entity6 ); one lesion was a @entity10 and one was an aldosteronoma. There were 10 @entity0 and two @entity0 (average age, 58 years; range, 40-77 years) in the study; average adrenal mass diameter was 3.9 cm (range, 1-8 cm). Average number of RF applications per adrenal mass was 2.7 (range, 1-5 applications); average time per application was 7.8 minutes (range, 4-13 minutes). An internally cooled single electrode was used in five sessions; an internally cooled cluster electrode was used in eight sessions. RESULTS: Average follow-up was 11.2 months (range, 1-46 months). Eleven of 13 lesions were treated successfully with RF ablation after one session. Successful treatment was defined as lack of enhancement of the treated region on follow-up CT images and resolution of the biochemical abnormality in two @entity0 . In two @entity0 with large adrenal lesions (4 and 8 cm in diameter), enhancement of residual tissue was observed after one treatment session; this finding was indicative of @entity4 . One @entity0 with @entity7 that resulted from chemotherapy had a small @entity9 , but no transfusion was required. No @entity0 developed @entity5 during the RF application. No @entity0 with @entity2 had recurrent @entity3 at the treated site, and this lack of recurrence indicated effective local control; 11 @entity0 had progression of @entity2 at extraadrenal sites. CONCLUSION: Preliminary data suggest that CT-guided RF ablation is an effective technique for local control of @entity11 .

title: XXXX : CT-guided radiofrequency ablation--preliminary results.

answer: @entity11


abstract: OBJECTIVES: Our goal was to determine the incidental Lund score for pediatric @entity0 without @entity1 ( @entity1 ). METHODS: Pediatric @entity0 with computed tomography scans of the orbit or brain were identified. @entity0 with a clinical history of sinonasal disorders or skeletal facial @entity2 were excluded. The remaining scans were scored according to the Lund-MacKay system. Pneumatization of the frontal and sphenoid sinuses was also recorded. A scaled Lund score was computed, and the mean Lund score for this normal population was determined. RESULTS: One hundred ninety-two computed tomography scans were examined (mean age, 9.0 years). The frontal sinuses and sphenoid sinuses were absent in 40.1% and 1.6% of cases, respectively. The mean scaled Lund score in this pediatric population without @entity1 was 2.81 (95% confidence interval, 2.40 to 3.22). This result differed statistically from a score of 0 (P < 0.001). Only 37 (19.3%) @entity0 had completely radiographically normal sinuses. CONCLUSIONS: The mean incidental Lund score in the absence of @entity1 approaches 3, and this should be considered when determining the diagnostic likelihood of @entity1 in pediatric @entity0 .

title: Incidental paranasal sinus imaging abnormalities and the normal Lund score in XXXX .

answer: @entity0


abstract: Heparin and heparin oligosaccharides prepared by @entity8 depolymerization were fractionated by affinity chromatography on immobilized @entity5 and by gel chromatography. The anticoagulant activities of high affinity heparin of Mr greater than or equal to 7,800 could be readily neutralized by the plasma protein @entity4 -rich glycoprotein (see also Lijnen, H.R., Hoylaerts, M., and Collen, D. (1983) J. Biol. Chem. 258, 3803-3808), whereas oligosaccharides falling below 18 @entity3 units (Mr 5,400) became increasingly resistant to neutralization. An @entity10 with characteristic marked ability to accelerate the inactivation of @entity6 by @entity5 retained greater than 50% of its activity even at a @entity4 -rich glycoprotein/oligosaccharide molar ratio of 500:1. @entity4 -rich glycoprotein, like the platelet-derived heparin neutralizing protein platelet factor 4 (Lane, D.A., Denton, J., Flynn, A.M., Thunberg, L. and Lindahl, U. (1984) Biochem J. 218, 725-732), therefore requires interaction with @entity3 sequences in addition to the @entity5 -binding pentasaccharide of heparin in order to efficiently express its antiheparin activity. Heparan @entity1 isolated from @entity2 intestinal mucosa ( @entity9 , Mr approximately 20,000) and from @entity0 aorta (HS II, Mr approximately 40,000) exhibited anti- @entity6 activities of 180 and 20 units/micromol [corrected], respectively. A fraction corresponding to about 5% of @entity9 bound with high affinity to immobilized @entity5 and contained all of the anticoagulant activity of the starting material. While these heparan @entity7 were readily neutralized by platelet factor 4, they were relatively resistant to neutralization by @entity4 -rich glycoprotein, although complete neutralization could be attained in the presence of molar excess of this protein. These findings may be of importance in relation (a) to the functional role of endogenous anticoagulant polysaccharides at the vascular wall and (b) to clinical situations in which heparin or heparin-related compounds are administered as exogenous anticoagulants.

title: Neutralization of heparin-related saccharides by XXXX -rich glycoprotein and platelet factor 4.

answer: @entity4


abstract: PURPOSE: Prior studies have reported @entity1 rates of converting non-tunneled dialysis catheters (NTDCs) to tunneled dialysis catheters (TDCs) versus de novo placement of TDCs using @entity4 . @entity3 , per the Center of Disease Control guidelines, has been exclusively used in our institution since 2005. Therefore, our study aims to determine whether there is a difference in @entity1 rates between conversion and de novo placement when utilizing @entity3 . MATERIALS AND METHODS: A retrospective analysis from 1/1/2009 to 8/10/2012 was performed of @entity0 who underwent placement of NTDCs, which were subsequently converted to TDCs and those who underwent de novo TDC placement. To assess the rate of @entity1 , the following data points were collected: date of procedure(s), indication, outcomes, site of catheter insertion, pre- and post-procedure laboratory values, complications, @entity1 rates within the life of the initially placed catheter, catheter days, and survival. RESULTS: The conversion cohort was composed of 205 @entity0 , 135 of whom were lost to follow-up, leaving 70 @entity0 . The de novo cohort included 70 randomly selected @entity0 . Of the 70 @entity0 who underwent conversion, 23 developed a @entity2 , with an @entity1 rate of 0.26 events per 100 catheter days. Of the 70 de novo catheters, 20 developed @entity1 with an @entity1 rate of 0.25 events per 100 catheters days. CONCLUSION: In this series, there is no difference in @entity1 rates between conversion and de novo TDC placement when utilizing @entity3 as the sterilization agent. However, these @entity1 rates are superior to those reported when using @entity4 .

title: Evaluation of XXXX rates in converted dialysis catheters versus de novo placement in the setting of @entity3 use.

answer: @entity2


abstract: PURPOSE: Prior studies have reported @entity1 rates of converting non-tunneled dialysis catheters (NTDCs) to tunneled dialysis catheters (TDCs) versus de novo placement of TDCs using @entity4 . @entity3 , per the Center of Disease Control guidelines, has been exclusively used in our institution since 2005. Therefore, our study aims to determine whether there is a difference in @entity1 rates between conversion and de novo placement when utilizing @entity3 . MATERIALS AND METHODS: A retrospective analysis from 1/1/2009 to 8/10/2012 was performed of @entity0 who underwent placement of NTDCs, which were subsequently converted to TDCs and those who underwent de novo TDC placement. To assess the rate of @entity1 , the following data points were collected: date of procedure(s), indication, outcomes, site of catheter insertion, pre- and post-procedure laboratory values, complications, @entity1 rates within the life of the initially placed catheter, catheter days, and survival. RESULTS: The conversion cohort was composed of 205 @entity0 , 135 of whom were lost to follow-up, leaving 70 @entity0 . The de novo cohort included 70 randomly selected @entity0 . Of the 70 @entity0 who underwent conversion, 23 developed a @entity2 , with an @entity1 rate of 0.26 events per 100 catheter days. Of the 70 de novo catheters, 20 developed @entity1 with an @entity1 rate of 0.25 events per 100 catheters days. CONCLUSION: In this series, there is no difference in @entity1 rates between conversion and de novo TDC placement when utilizing @entity3 as the sterilization agent. However, these @entity1 rates are superior to those reported when using @entity4 .

title: Evaluation of @entity2 rates in converted dialysis catheters versus de novo placement in the setting of XXXX use.

answer: @entity3


abstract: UNASSIGNED: The medfly @entity1 is one of the most important pests for horticulture worldwide. The knowledge about anatomy and function of the medfly olfactory system is still limited. The first brain structure to process olfactory information in insects is the @entity0 ( @entity0 ), which is composed of its functional and morphological units, the olfactory glomeruli. Here, we present a morphological three-dimensional reconstruction of @entity0 glomeruli in adult brains. We used unilateral antennal backfills of olfactory receptor neurons (ORNs) with neural tracers, revealing the @entity0 structure. We recorded confocal stacks acquired from whole-mount specimens, and analyzed them with the software AMIRA. The ALs in @entity1 are organized in glomeruli which are more tightly packed in the anterior part than the posterior one. Axons of ORNs bilaterally connect the ALs through a commissure between the two ALs. This commissure is formed by several distinct fascicles. Contralateral dye transfer suggests the presence of gap junctions connecting ORNs from both antennae. There was no statistical difference between the average volumes of female ALs (204,166      12,554   m(3)) and of male ALs (190,287      11,823   m(3)). In most specimens, we counted 53 glomeruli in each @entity0 , seven of which were sexually dimorphic in size.

title: Morphological characterization of the antennal lobes in the XXXX @entity1 .

answer: @entity1


abstract: UNASSIGNED: The medfly @entity1 is one of the most important pests for horticulture worldwide. The knowledge about anatomy and function of the medfly olfactory system is still limited. The first brain structure to process olfactory information in insects is the @entity0 ( @entity0 ), which is composed of its functional and morphological units, the olfactory glomeruli. Here, we present a morphological three-dimensional reconstruction of @entity0 glomeruli in adult brains. We used unilateral antennal backfills of olfactory receptor neurons (ORNs) with neural tracers, revealing the @entity0 structure. We recorded confocal stacks acquired from whole-mount specimens, and analyzed them with the software AMIRA. The ALs in @entity1 are organized in glomeruli which are more tightly packed in the anterior part than the posterior one. Axons of ORNs bilaterally connect the ALs through a commissure between the two ALs. This commissure is formed by several distinct fascicles. Contralateral dye transfer suggests the presence of gap junctions connecting ORNs from both antennae. There was no statistical difference between the average volumes of female ALs (204,166      12,554   m(3)) and of male ALs (190,287      11,823   m(3)). In most specimens, we counted 53 glomeruli in each @entity0 , seven of which were sexually dimorphic in size.

title: Morphological characterization of the antennal lobes in the @entity1 XXXX .

answer: @entity1


abstract: A home measurement monitoring system has been developed for assessing progress and planning changes in care for @entity0 with @entity2 . Daily diary recording of specified measurements, quantitative symptom data, and free text are to be used for early detection of deteriorating trends before serious complications develop. Daily measurements made at home are lung capacity, body weight, breathing rate, and pulse. The program has been in place for the past two years, and has maintained a 75-80% consistent diary response rate among the 111 @entity0 initially committed to the program. Measurements are easy to perform, equipment design is simple and rugged, and data handling routines designed for the program using the INSIGHT clinical data base system perform satisfactorily. Checking for data entry errors and validity checks of home measurements are a regular part of the data handling activity. @entity0 acceptance and long-term compliance in this program agrees very favorably with reports of other diary programs in @entity1 . Diary compliance was significantly greater among younger @entity0 and those who lived long distances from the hospital. This study has demonstrated that home monitoring is a feasible program for @entity0 with @entity2 . It presents the possibility of detecting adverse health trends earlier than is now practical, so that @entity0 can be treated before serious complications develop, thereby preventing the large fluctuations in health status that often accompany @entity2 .

title: Feasibility and compliance studies of a home measurement monitoring program for XXXX .

answer: @entity2


abstract: UNASSIGNED: The present study aimed to assess the activity of @entity2 ( @entity2 ) containing bacteriocins on the formation and maintenance of biofilms developed by @entity3 , and the associated effect of @entity4 and @entity1 ( @entity1 ) on the formed biofilm. @entity2 from 9 @entity0 bacteria (LAB) strains was tested for inhibitory activity against 85 @entity3 isolates and 21 LAB strains. Then, 12 @entity3 strains were selected based on genetic profiles and sensitivity to @entity2 and were subjected to an in vitro assay to assess biofilm formation in microtiter plates, considering different culture media and incubation conditions. Based on these results, 6 @entity3 strains were subjected to the same in vitro procedure to assess biofilm formation, being co-inoculated with @entity2 . In addition, these strains were subjected to the same in vitro procedure, modified by adding the @entity2 after biofilm formation. Relevant decrease in biofilm formation was observed in the first experiment, but @entity2 added after biofilm formation did not eliminate them. @entity2 from @entity5 ET31 were selected due to its anti-biofilm activity, being associated to @entity1 at different concentrations and tested for biofilm control of three strains of @entity3 , using the same in vitro procedure described previously. Concentrated @entity4 presented poor performance in eliminating formed biofilms, and @entity1 concentration presented no evident interference on biofilm elimination. Twelve selected @entity3 strains were positive for investigated virulence makers and negative for luxS gene, recognized as being involved in biofilm formation. Selected @entity3 strains were able to produce biofilms under different conditions. CFSs have the potential to prevent biofilm formation, but they were not able to destroy already formed biofilms. Nevertheless, low concentrations of @entity2 combined with @entity1 caused a relevant reduction in already formed biofilms, but this association was not able to eliminate them. The activity of selected @entity2 was demonstrated against @entity3 -formed biofilms, being more effective when associated to @entity1 at different concentrations.

title: In Vitro Evaluation of @entity4 Activity Against XXXX Biofilm Formation.

answer: @entity3


abstract: UNASSIGNED: The present study aimed to assess the activity of @entity2 ( @entity2 ) containing bacteriocins on the formation and maintenance of biofilms developed by @entity3 , and the associated effect of @entity4 and @entity1 ( @entity1 ) on the formed biofilm. @entity2 from 9 @entity0 bacteria (LAB) strains was tested for inhibitory activity against 85 @entity3 isolates and 21 LAB strains. Then, 12 @entity3 strains were selected based on genetic profiles and sensitivity to @entity2 and were subjected to an in vitro assay to assess biofilm formation in microtiter plates, considering different culture media and incubation conditions. Based on these results, 6 @entity3 strains were subjected to the same in vitro procedure to assess biofilm formation, being co-inoculated with @entity2 . In addition, these strains were subjected to the same in vitro procedure, modified by adding the @entity2 after biofilm formation. Relevant decrease in biofilm formation was observed in the first experiment, but @entity2 added after biofilm formation did not eliminate them. @entity2 from @entity5 ET31 were selected due to its anti-biofilm activity, being associated to @entity1 at different concentrations and tested for biofilm control of three strains of @entity3 , using the same in vitro procedure described previously. Concentrated @entity4 presented poor performance in eliminating formed biofilms, and @entity1 concentration presented no evident interference on biofilm elimination. Twelve selected @entity3 strains were positive for investigated virulence makers and negative for luxS gene, recognized as being involved in biofilm formation. Selected @entity3 strains were able to produce biofilms under different conditions. CFSs have the potential to prevent biofilm formation, but they were not able to destroy already formed biofilms. Nevertheless, low concentrations of @entity2 combined with @entity1 caused a relevant reduction in already formed biofilms, but this association was not able to eliminate them. The activity of selected @entity2 was demonstrated against @entity3 -formed biofilms, being more effective when associated to @entity1 at different concentrations.

title: In Vitro Evaluation of XXXX Activity Against @entity3 Biofilm Formation.

answer: @entity4


abstract: Thallium-201 single photon emission computed tomography (SPECT) is a new method for the scintigraphic visualization of the left ventricular myocardium. With SPECT a three-dimensional imaging by computerized slicing of the myocardium in various axes is possible. To investigate the capabilities of this new imaging technique, detection and quantification of remote transmural @entity2 were compared with ventriculographic, coronarographic and electrocardiographic findings. 31 of 80 investigated @entity0 had had a prior @entity1 . The left ventricular myocardium was divided into 7 regions in the scintigraphic as well as in the angiographic studies. In a total of 560 segments the sensitivity of SPECT for @entity2 detection was 87.5% with a specificity of 99.8%. @entity2 which were not detected scintigraphically were relatively small (mean 13.5% of the circumference). To quantify the @entity2 , the size of the defect was determined scintigraphically from a sagittal long axis and two short axes, and the images compared with angiographic @entity2 sizes (% of the circumference) according to the method of Feild et al. A good correlation without overestimation of the size by one method (SPECT defect = 0.93 X ventriculographic defect - 1.2%; r = 0.7, p less than 0.001) was obtained. Also a good separation of the perfusion areas of the coronary arteries due to the three-dimensional imaging with SPECT was possible. Thus, by employing Thallium-201 SPECT of the left ventricular myocardium exact localization and quantification of transmural @entity1 with a positive predictive value of 98% can be achieved.

title: [Detection, quantification and localization of XXXX : comparison of thallium single photon emission computer tomography with biplane angiography].

answer: @entity1


abstract: PURPOSE: Infusion of @entity8 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity7 /IL12, has induced @entity2 regression in a minority of @entity1 with metastatic treatment-refractory @entity8 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity3 @entity2 model, we cultured T cells derived from @entity3 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity7 / @entity10 could uniquely mediate complete regression of spontaneous @entity2 . @entity7 / @entity10 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity4 and @entity9 (P < 0.05). Moreover, @entity2 -infiltrating @entity5 (+) cells were significantly increased after the infusion of @entity7 / @entity10 cultured T cells as compared with @entity2 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity7 / @entity10 cultured cells was mediated by @entity5 T cells. Depletion of @entity4 or @entity9 , but not IFNy, abrogated the @entity2 growth inhibition induced by the @entity7 / @entity10 T cells and markedly decreased the influx of @entity5 into @entity2 . Finally, @entity7 / @entity10 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity6 /Th17 phenotype. CONCLUSIONS: Expansion of @entity8 vaccine-primed T cells with @entity7 / @entity10 may have the potential to effectively mediate @entity2 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of XXXX / @entity10 -Cultured Polyfunctional Neu-Specific T Cells Is @entity4 / @entity9 Dependent.

answer: @entity7


abstract: PURPOSE: Infusion of @entity8 -specific T cells, derived from vaccine-primed @entity1 and expanded with @entity7 /IL12, has induced @entity2 regression in a minority of @entity1 with metastatic treatment-refractory @entity8 (+) @entity0 . We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity. EXPERIMENTAL DESIGN: Using the TgMMTV-neu @entity3 @entity2 model, we cultured T cells derived from @entity3 immunized with a previously defined neu class II peptide, p98-114 (neu p98), and evaluated different cytokine combinations for expansion. RESULTS: Infusion of neu p98-specific T-cell lines derived from all cytokine conditions evaluated resulted in significant antitumor activity compared with infused na  ve splenocytes (P < 0.05). T cells cultured with @entity7 / @entity10 could uniquely mediate complete regression of spontaneous @entity2 . @entity7 / @entity10 cultured neu-specific T cells demonstrated a different cytokine secretion pattern as compared with other cultured T cells; secreting high levels of @entity4 and @entity9 (P < 0.05). Moreover, @entity2 -infiltrating @entity5 (+) cells were significantly increased after the infusion of @entity7 / @entity10 cultured T cells as compared with @entity2 treated with T cells expanded under other cytokine conditions (P < 0.001). The antitumor effect of the infusion of @entity7 / @entity10 cultured cells was mediated by @entity5 T cells. Depletion of @entity4 or @entity9 , but not IFNy, abrogated the @entity2 growth inhibition induced by the @entity7 / @entity10 T cells and markedly decreased the influx of @entity5 into @entity2 . Finally, @entity7 / @entity10 -cultured human antigen specific T cells also displayed a similar polyfunctional @entity6 /Th17 phenotype. CONCLUSIONS: Expansion of @entity8 vaccine-primed T cells with @entity7 / @entity10 may have the potential to effectively mediate @entity2 regression when used in adoptive transfer. Clin Cancer Res; 22(9); 2207-16.   2015 AACR.

title: The Antitumor Efficacy of @entity7 / XXXX -Cultured Polyfunctional Neu-Specific T Cells Is @entity4 / @entity9 Dependent.

answer: @entity10